Alex Thompson
Stock Analyst at Stifel
(1.43)
# 1,597
Out of 4,667 analysts
30
Total ratings
45%
Success rate
-10.46%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Alex Thompson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ASND Ascendis Pharma | Maintains: Buy | $200 → $207 | $124.38 | +66.43% | 2 | Nov 15, 2024 | |
| ORKA Oruka Therapeutics | Initiates: Buy | $49 | $22.20 | +120.72% | 1 | Oct 11, 2024 | |
| ARGX argenx SE | Maintains: Buy | $485 → $500 | $591.82 | -15.51% | 4 | Jun 24, 2024 | |
| THRD Third Harmonic Bio | Initiates: Buy | $23 | $11.62 | +97.93% | 1 | Jun 18, 2024 | |
| SYRE Spyre Therapeutics | Reiterates: Buy | $36 → $54 | $27.50 | +96.36% | 2 | Mar 26, 2024 | |
| DNTH Dianthus Therapeutics | Initiates: Buy | $44 | $20.77 | +111.84% | 1 | Feb 15, 2024 | |
| VTYX Ventyx Biosciences | Maintains: Hold | $6 → $2 | $1.72 | +16.28% | 5 | Dec 18, 2023 | |
| TVTX Travere Therapeutics | Maintains: Hold | $8 → $10 | $17.86 | -44.01% | 2 | Dec 18, 2023 | |
| MLTX MoonLake Immunotherapeutics | Maintains: Buy | $66 → $69 | $49.82 | +38.50% | 2 | Dec 18, 2023 | |
| ACRS Aclaris Therapeutics | Maintains: Hold | $2 → $1 | $3.96 | -74.75% | 4 | Dec 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $40 | $19.79 | +102.12% | 2 | Sep 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $40 | $1.07 | +3,638.32% | 1 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $28 → $34 | $26.17 | +29.92% | 2 | Jul 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $33 | $12.73 | +159.23% | 1 | Dec 14, 2022 |
Ascendis Pharma
Nov 15, 2024
Maintains: Buy
Price Target: $200 → $207
Current: $124.38
Upside: +66.43%
Oruka Therapeutics
Oct 11, 2024
Initiates: Buy
Price Target: $49
Current: $22.20
Upside: +120.72%
argenx SE
Jun 24, 2024
Maintains: Buy
Price Target: $485 → $500
Current: $591.82
Upside: -15.51%
Third Harmonic Bio
Jun 18, 2024
Initiates: Buy
Price Target: $23
Current: $11.62
Upside: +97.93%
Spyre Therapeutics
Mar 26, 2024
Reiterates: Buy
Price Target: $36 → $54
Current: $27.50
Upside: +96.36%
Dianthus Therapeutics
Feb 15, 2024
Initiates: Buy
Price Target: $44
Current: $20.77
Upside: +111.84%
Ventyx Biosciences
Dec 18, 2023
Maintains: Hold
Price Target: $6 → $2
Current: $1.72
Upside: +16.28%
Travere Therapeutics
Dec 18, 2023
Maintains: Hold
Price Target: $8 → $10
Current: $17.86
Upside: -44.01%
MoonLake Immunotherapeutics
Dec 18, 2023
Maintains: Buy
Price Target: $66 → $69
Current: $49.82
Upside: +38.50%
Aclaris Therapeutics
Dec 18, 2023
Maintains: Hold
Price Target: $2 → $1
Current: $3.96
Upside: -74.75%
Sep 13, 2023
Reiterates: Buy
Price Target: $40
Current: $19.79
Upside: +102.12%
Aug 9, 2023
Initiates: Buy
Price Target: $40
Current: $1.07
Upside: +3,638.32%
Jul 18, 2023
Maintains: Buy
Price Target: $28 → $34
Current: $26.17
Upside: +29.92%
Dec 14, 2022
Initiates: Buy
Price Target: $33
Current: $12.73
Upside: +159.23%